Atea Pharmaceuticals Inc (AVIR) earnings · next report Nov 11, 2026
AVIR earnings call
Call time not announced yet · report Wed, Nov 11
Company investor site: ir.ateapharma.com. IR page from the company's last earnings release (Aug 12, 2026).
Next report
Wed, Nov 11, 2026
After the close · In 7 days
Quarter ended Sep 2026
- EPS consensus
- −$0.50 Range −$0.59 – −$0.422 analystsYear ago −$0.53
- Revenue consensus
- $0 Range $0 – $01 analysts
EPS estimate trend
- 90 days ago−$0.55
- 60 days ago−$0.55
- 30 days ago−$0.55
- 7 days ago−$0.55
- Now−$0.51
Consensus +7.3% over 90 days. Last 30 days: 1 up, 1 down revisions.
Date and consensus: EODHD earnings calendar and estimates, refreshed every 6 hours. “Confirmed” means the provider lists the report session, which it sets once the company announces; “Estimated” is the provider’s expected date.
Follow AVIR into its report
Save it to a free watchlist (no card). Alerts when the date moves or results land are part of Pro.
Earnings move
- Options price in (Nov 11)
- — No options snapshot for this report yet (taken daily in the 7 days before a report, for stocks with listed options).
- Average move after earnings
- ±5.7% Absolute close-to-close move, 2 reports
Options-implied move: the at-the-money straddle (call + put) on the first expiry after the report, divided by the stock’s close, from EODHD end-of-day option chains. It is what the options market prices as the absolute move to that expiry, not a forecast of direction. Move: close before the news → close after it (before the open: prior close → report-day close; after the close: report-day close → next close), adjusted for splits and dividends, from EODHD end-of-day prices. Reports with an unannounced time are not averaged: both candidate moves are stored instead. Per-report moves, gaps, moves vs SPY and the sector, beat/miss asymmetry and implied vs actual are in Lician Pro below.
Latest result
EPSGAAP
−$0.41
vs −$0.56 est. +26.8%
GAAP diluted EPS, SEC 10-Q
Revenue
—
No revenue consensus stored
EPS actuals are checked against the SEC filing and the company’s earnings press release (8-K EX-99.1). A company that reports only GAAP EPS is graded on its SEC diluted EPS; one that reports adjusted EPS is graded on the provider’s adjusted figure when the release confirms it. A figure that matches neither is shown as unverified, with no beat or miss. Revenue actuals come from the SEC filing of the same quarter where we have it.
Beat / miss history
- Beat EPS in 2 of 4
- Aug 12, 2026BeatEPS −$0.41GAAP vs −$0.56 +26.8%Rev — vs —
- May 13, 2026MissEPS −$0.57GAAP vs −$0.56 −3.4%Rev — vs —
- Nov 12, 2025MissEPS −$0.53GAAP vs −$0.41 −29.3%Rev — vs —
- Aug 7, 2025BeatEPS −$0.44GAAP vs −$0.46 +4.3%Rev — vs —
| Reported | Quarter | EPS est. | EPS actual | Surprise | Revenue est. | Revenue | Surprise |
|---|---|---|---|---|---|---|---|
| Aug 12, 2026 | Jun 2026 | −$0.56 | −$0.41GAAP | +26.8% | — | — | — |
| May 13, 2026 | Mar 2026 | −$0.56 | −$0.57GAAP | −3.4% | — | — | — |
| Nov 12, 2025 | Sep 2025 | −$0.41 | −$0.53GAAP | −29.3% | — | — | — |
| Aug 7, 2025 | Jun 2025 | −$0.46 | −$0.44GAAP | +4.3% | — | — | — |
Earnings documents
No earnings 8-K (item 2.02) is stored for this report yet. All AVIR filings: SEC filings.
Documents link to SEC EDGAR. Lician does not publish earnings-call transcripts.
Healthcare peers with similar quant ratings
AVIR is rated 2.55 of 5 among 532 rated Healthcare stocks (Lician quant rating, Nov 4, 2026). How the rating works
- IMUX earnings2.58 · Hold · stock
- PRAX earnings2.58 · Hold · stock
- GLUE earnings2.57 · Hold · stock
- AMWL earnings2.55 · Hold · stock
- ACHC earnings2.54 · Hold · stock
- RGEN earnings2.53 · Hold · stock
- KMTS earnings2.52 · Hold · stock
- KOD earnings2.51 · Hold · stock
| Quarter | Revenue | EPS | YoY |
|---|---|---|---|
| Q2 FY26 | — | −$0.41 | — |
| Q1 FY26 | — | −$0.57 | — |
| Q3 FY25 | — | −$0.53 | — |
| Q2 FY25 | — | −$0.44 | — |
Atea Pharmaceuticals Inc (AVIR) is a biotechnology company listed on US.
No cached income statement for AVIR yet, so there is no earnings base to recap.
When the next AVIR 8-K Item 2.02 lands, this page should move. Until then the SEC archive is the source.
Period-over-period revenue change is not in cache for AVIR. We will not invent a beat or miss.
Not investment advice. Full AVIR research stays on the stock page; the tape stays on the quote page.
AVIR earnings FAQ
When is AVIR's next earnings date?
Atea Pharmaceuticals Inc (AVIR) is expected to report on Wed, Nov 11, 2026, after the close. The provider lists the session, which it sets once the company announces. Consensus EPS is −$0.50.
When is the AVIR earnings call?
Atea Pharmaceuticals Inc has not announced the time of its next earnings call in an SEC filing yet. Its investor relations page (ir.ateapharma.com) lists the webcast when it is scheduled.
Did AVIR beat earnings estimates last quarter?
Yes. On Aug 12, 2026 Atea Pharmaceuticals Inc (AVIR) reported adjusted EPS of −$0.41 against a −$0.56 consensus (+26.8%), a beat.
How often does AVIR beat EPS estimates?
Atea Pharmaceuticals Inc (AVIR) beat the EPS consensus in 5 of its last 9 reported quarters.
Not investment advice.